Pharma C Investments - Board Change and Appointment of Corporate Advisor

Pharma C Investments Plc

("Pharma C" or the "Company")

Board Change, Appointment of Corporate Advisor, Grant of Options and Warrants

Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on ancillary businesses, is pleased to provide the following updates to shareholders.

Appointment of Toby Shillito

Pharma C has appointed Toby Shillito to the Board as Chief Business Development Officer. Toby has over seven years' experience in designing and operating licensed facilities to cultivate medical cannabis in Europe, as well as assessing the value of technological innovations in this space.

Toby established the Cannabis Industry Council's Corporate Responsibility Group in Q2 of this year. He has also founded iGeneration.Life, a pharmaceutical company pursuing Medicines and Healthcare products Regulatory Agency (MHRA) licenses for cannabis based medicinal products in the UK. Toby's vast experience in the medical cannabis industry enables him to identify business models that are likely to succeed in the post-prohibition era, as well as assist cannabis companies to comply with their social and environmental responsibilities.

Except as set out above, there is no further information regarding Toby Shillito, that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Appointment of Novum Securities Limited as AQSE Corporate Advisor

Pharma C has appointed Novum Securities Limited as its AQSE Corporate Advisor with immediate effect.

Chana Greenberg, CEO of Pharma C Investments, commented, "I am delighted to be welcoming Toby to our Board. His wealth of experience and knowledge in the cultivation of medical cannabis is unmatched and will be invaluable as we look to make our initial investments.

Along with this, I am pleased to welcome Novum Securities as our Corporate Advisor. We look forward to working closely with them as we continue to grow our Company. I would like to personally thank Beaumont Cornish for their exceptional guidance and advice during our AQSE admission earlier this year.

The company is currently looking at a number of potential investments and further announcements will be made in due course."

Grant of Options and Warrants

Pharma C announces that the Company has granted to Gavin Sathianathan (Investment Strategy Director) an aggregate of 12,000,000 options over ordinary shares of 0.7p each in the Company, and has granted to  Toby Shillito (Chief Business Development Officer) an aggregate of 5,000,000 options over ordinary shares of 0.7p pence each in the Company (the "Options").

The options are exercisable anytime between the first and fifth anniversaries of granting

In total 47.83 million share options are now outstanding representing approximately 17.7 per cent of the Company's current issued share capital.  The total number of Ordinary Shares currently in issue is 269,857,144.

In addition, 20,000,000 warrants have been granted exercisable at 0.7 p anytime until the fifth anniversary of grant, in lieu of services provided in connection with the recent Admission to AQSE. 

The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.

This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

The Directors of Pharma C Investments plc take responsibility for this announcement.

- Ends -

For additional information please contact:

About Pharma C Investments

Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.